Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.

Bone - 1 Jan 2017

Thrailkill Kathryn M, Nyman Jeffry S, Bunn R Clay, Uppuganti Sasidhar, Thompson Katherine L, Lumpkin Charles K, Kalaitzoglou Evangelia, Fowlkes John L

Abstract excerpt

Skeletal co-morbidities in type 1 diabetes include an increased risk for fracture and delayed fracture healing, which are intertwined with disease duration and the presence of other diabetic complications. As such, chronic hyperglycemia is undoubtedly a major contributor to these outcomes, despite standard insulin-replacement therapy. Therefore, using the streptozotocin (STZ)-induced model of hypoinsulinemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Bone and Bones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Diseases, Metabolic

Share to Bone Resorption

Share to Diabetes Mellitus, Type 1

Share to Fibroblast Growth Factor-23

Share to Linear Models

Share to Mice, Inbred DBA

Source

Open in PubMed Open full text

Identifiers

PMID: 27989651
DOI: 10.1016/j.bone.2016.10.026
PMCID: PMC5826569

Genes

INS
FGF23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.PMID 27989651Read ↗

Mouse models of type 1 diabetes and their use in skeletal researchSemantic proximity Read ↗

The complex pathophysiology of bone fragility in obesity and type 2 diabetes mellitus: therapeutic targets to promote osteogenesisSemantic proximity Read ↗

Integrated Phenotypic and Transcriptomic Analyses of Osteoporosis in Type 2 Diabetic MiceSemantic proximity Read ↗

Osteoporosis in patients with diabetes mellitus.Semantic proximity Read ↗

Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher Advanced Glycation End-products (AGEs) content and reduced bone strengthSemantic proximity Read ↗

Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes.Semantic proximity Read ↗

Runt-Related Transcription Factor 2 (RUNX2) and RUNX2-Related Osteogenic Genes Are Down-Regulated throughout Osteogenesis in Type 1 Diabetes MellitusSemantic proximity Read ↗

Profiling bone status indices reveals evidence of a low-turnover bone phenotype in type 2 diabetes: findings from the DiaFALL cohort.Semantic proximity Read ↗

Genetic and pharmacologic modulation of RAGE rescues the diabetes-mediated impairments to bone at multiple length scalesSemantic proximity Read ↗

Complications in the spine associated with type 2 diabetes: The role of advanced glycation end-productsSemantic proximity Read ↗

The Role of Bone Morphogenetic Proteins in Diabetic ComplicationsSemantic proximity Read ↗

The sex-specific effects of RAGE signaling and Type 2 Diabetes on mouse cortical bone mechanics, structure, and material propertiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.